I think on average it's difficult for people in most countries outside the US to pay those levels of pricing. The US is unique in that the prices aren't regulated and most pharmaceuticals are covered by some type of insurance.
I missed the below story when it was issued a couple months ago. At least this analyst is sticking with his $3 price target quarter after quarter even while the stock price seems stuck in the 40 cent range.
Agreed. I had a look before in the Pfizer deal, and have to say while there was limited information on the specifics it does seem to have been a horrid deal that previous CEO made for Protalix. I mean PLX got something like 60 million dollars for transferring ex-Brazil global right. And I remember someone on this board earlier had show that Elelyso was being sold by Pfizer in a list of the most expensive drugs in the word. Something astronomical in the hundreds of thousands per patient per year. The fact that Pfizer still has their program going and buying more Elelyso just shows that the market need for PLX's original product still persists. Crazy deal if you ask mean and almost selling the product to Pfizer at cost it seems.
Again I see AA designation as the only near-term potential catalyst. But to be fair, I'm just continuing to accumulate. The multiples in market cap value to be achieved from the current 59 million is incredible.
News 
Market Data 
Discover 
